TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04984005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity exercise training
Description: The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a low-intensity exercise training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training
Description: The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a moderate-intensity exercise training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent high intensity exercise training
Description: The exercise method is broadcast gymnastics and sports dance. Through the design of different exercise intensities, This arm receives a high-intensity exercise training.
Study: NCT06155097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transversus thoracis muscle plane block (TTP)
Description: patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard monitors. After determining the anterior T4-T5 interspace using US, the US probe places in the longitudinal plane 1 cm lateral to the sternal border. A parasternal sagittal view of the internal intercostal muscle and the transversus thoracis muscle between the fourth and fifth rib will be visualized above the pleura. A 22-gage needle will be inserted in plane to the transducer with the tip of the needle located in the TTP between the internal intercostal and transversus thoracis muscles. After excluding intravascular and intrapleural placement, LA will administer with intermittent aspiration (administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side. After block administration, the patients will be monitored for LA toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parasternal intercostal nerve block (PSI block)
Description: patient in supine position with chest exposed and monitored by beat-to-beat arterial tracing and standard. Ultrasound scan will be performed from lateral to medial in the intercostal space. The intercostal muscles and pleura will be identified along the lower border of the rib. At the lateral border of the sternum, internal thoracic vessels lying anterior to transverse thoracic muscle are identified. The needle will be inserted in-plane to follow its tip using 4-mL injections per intercostal space across levels two through six bilaterally, for a total of 40 mL (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone)
Study: NCT05763303

Intervention type: OTHER
Group type: OTHER
Intervention: educational program
Description: interventional program consists of educational part and training part in case of agreement of participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program
Description: interventional program consists of educational part and training part in case of agreement of participants
Study: NCT05090527

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk stratification
Description: advanced penicillin challenge after risk stratification

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk stratification
Description: advanced penicillin challenge after risk stratification

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Risk stratification
Description: advanced penicillin challenge after risk stratification
Study: NCT05689788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy
Description: punctual technique on the 6 bilateral points of the cervical region and shoulder girdle, to be followed by a sweep technique on both trapezius muscles (upper portions). The parameters proposed by Dundar et al. will be used: an average power of 3 W, 60 J per point (360 J), and 500 J for manual scanning (1000 J). For the application of laser therapy, the 12 W BTL-6000 equipment that emits at 1064 nm wavelengths will be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stretching exercise
Description: Three sets of bilateral passive static stretching will be performed for the upper trapezius, levator scapulae, and scalene muscles. Each series will last 30 seconds, followed by a 30-second rest interval. The exercises will be carried out with the participant in a seated position in a chair with a backrest.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High-intensity laser therapy
Description: Intervention in which the therapist performs a HILT simulation application, performing all of the steps and movements for an administration without actually receiving the treatment.
Study: NCT05438758

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Almond Therapy
Description: Participants will receive 12 remote session conducted by video or phone. Therapy sessions consist of modules selected using a shared decision making process, tailored so that it is personally meaningful to each participants. Participants will also receive supportive text messages on selective days over the 3 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal ketamine (Esketamine)
Description: Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Intranasal ketamine (Esketamine)
Description: Participants will receive 56 mg or 84 mg once a week for 4 weeks followed by 56 mg or 84 mg once every two weeks for 8 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will continue to received the therapy that their treating physician felt was appropriate at the time of enrolment in the study. These can include cognitive behavioural therapy, supportive psychotherapy or mindfulness, support groups, physical activity or relaxation.
Study: NCT04976647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HLX10+chemo
Description: HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10+HLX07+chemo
Description: HLX07 1500mg IV q3w; HLX10 300mg IV Q3W; carboplaitin (AUC5 or 6) IV Q3W + nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10+HLX07
Description: HLX07 1500mg IV q3w; HLX10 300mg IV Q3W;
Study: NCT05222594

Intervention type: OTHER
Group type: OTHER
Intervention: Behavioral tasks during intracranial monitoring
Description: Participants will listen to sentences and stories while neural data are recorded through electrodes placed for clinical purposes.
Study: NCT05494970

Intervention type: OTHER
Intervention: Accompaniment by the dental assistant.
Description: Inclusion visit (before radiotherapy treatment):~* oral hygiene education (prevention of complications related to radiotherapy) will be provided by the dental assistant.~* a written information guide on oral hygiene will be given to the patient.~* the questionnaire entitled Motivation and oral hygiene behavior will be completed by the patient.~End of study visit (three months post-radiotherapy):~• The Motivation and oral hygiene behavior and the satisfaction questionnaires will be completed by the patient.
Study: NCT05411991

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UNa measurement after intravenous loop diuretic bolus
Description: Sodium concentration is measured on a urine spot sample, collected 30-120 min after administration of every protocol-specified intravenous bumetanide dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide 500 mg OD
Description: Upfront use of intravenous acetazolamide 500 mg OD as part of the diuretic treatment, unless hypernatremia (\>145 mmol/L) or metabolic acidosis (bicarbonate \<22 mmol/L) is present at the moment of the scheduled administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous bumetanide TID
Description: An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR \>45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
Study: NCT05052918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 1 hour of moderate-intensity aerobic exercise 3 days a week for 12 weeks
Study: NCT05292053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Description: TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
Study: NCT05758103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
Description: Non-surgical professional mechanical debridement and probiotic supplement Limosilactobacillus reuteri Prodentis® (combining L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 strains)
Study: NCT03193242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Asthma Management System: eAMS
Description: Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe.
Study: NCT06230172

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Weaning incubator (heat) at an lower postnatal weight
Description: Infants in the intervention group are weaned in the same manner as the infants in the control arm; however, the wean begins at a lower postnatal weight.~Our institutional guidelines for weaning infants from incubator to crib was unchanged for both groups.
Study: NCT06507072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Rock Climbing Program
Description: Twelve week rock climbing program. The program will take place once per week over the course of twelve weeks.
Study: NCT05401409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 70mls beetroot juice (400mg nitrate) given daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: 70mls beetroot juice (nitrate-depleted) given daily for 4 weeks
Study: NCT04865107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 daily doses of up to 90-million cells/unit dose (cumulative dose of up to 270 million UC-MSCs)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PlasmaLyte A and 5% Human Albumin
Study: NCT05894863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart flex stent
Description: Smart flex stent will be used for femoropopliteal occlusive lesions.
Study: NCT05720663

Intervention type: OTHER
Intervention: Standard of care
Description: Participants will receive the standard of care for their condition
Study: NCT04769102

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: seat cushions
Description: flat versus contoured customized seat cushions
Study: NCT05582759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: teleCBT-I + SH/ReadiWatchTM
Description: Participants receive real time feedback on sleep metrics, education on sleep hygiene and a four-week virtual cognitive behavioral therapy for insomnia intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SH/ReadiWatchTM
Description: Participants receive real time feedback on sleep metrics and education on sleep hygiene
Study: NCT05206383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive message - placebo
Description: Subjects who will be told that the applied plastering method significantly increases muscle strength (positive message - placebo).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative message - nocebo
Description: Subjects who will be told that the applied plastering method has no effect on muscle strength (negative message - nocebo).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral message
Description: Subjects who will be told that the applied plastering method is currently under investigation and the investigators do not know its effects (neutral message).
Study: NCT05597449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YouTube videos on care after urologic surgery
Description: Supplemental educational videos regarding care following pediatric urologic surgery
Study: NCT05446142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib capsule formulation (CAP)
Description: A single encorafenib dose of the CAP formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib capsule formulation (CAP)
Description: A single encorafenib dose of the CAP formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib first formulation
Description: first formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib first formulation
Description: first formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib second formulation
Description: second formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib second formulation
Description: second formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole tablet
Description: Proton-pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole tablet
Description: Proton-pump inhibitor
Study: NCT05999591

Intervention type: PROCEDURE
Intervention: Intrauterine insemination
Description: Transfer of sperm into the fallopian tube through a specialised cannula
Study: NCT04709653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupation-based nursing program
Description: First Session (Rug Weaving Activity): The child and the caregiver will be informed about the purpose and process of the research. The researcher will show in detail how to use rug weaving materials. Rug weaving activity will be started with the child. At the end of the 30-minute practice, the second session with the child will be planned and the session will be ended.~Second Session (Rug Weaving Event Continues). Third Session (Rug Weaving Activity Continues): Rug weaving activity will be completed and the session will be ended by planning the fourth session with the child.~Fourth Session (Origami Activity): A figure will be made with origami with the child. The child will be given support to make another figure. The fifth session hour will be planned with the child and the session will be ended.~Fifth Session (Shape Making Activity with Chenille): A shape will be created with the child with chenille.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Routine nursing care
Study: NCT05436925

Intervention type: DEVICE
Intervention: Dexcom G6 sensor Continuous Glucose Monitor (CGM)
Description: The device used as part of the study is to obtain results for glucose testing for research only and not for diagnostic purposes.
Study: NCT05106205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5213 10mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5213 10mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5213-R 10mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5213-R 10mg
Description: single dose administration (one tablet once a day)
Study: NCT06224777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5% Albumin (human) Solution
Description: Albumin is a biological product derived from human blood donors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paeds solution
Description: Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paeds solution
Description: Paeds solution contains dextrose 4.3%, and Sodium Chloride 0.18%
Study: NCT06023251

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Nutrition
Description: Nutritional care plan implementation, including~* A step-up and step-down nutritional protocol guided by caloric and protein ratio~* Monitoring plan including daily nutritional intake assessment by a dietician and (para)medical supervision by a nutrition support pharmacist and nurse concerning dysphagia, refeeding syndrome, electrolytes abnormalities and access issues~* Indirect calorimetry measurements to assess metabolic needs and body impedance analysis to assess body composition on regular time points~* Dedicated and specialized dietician and nurse involvement~* Adaptive communication policy (translating to native language) and culturally appropriate food regimens and artificial nutrition.
Study: NCT06462170

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Boost Original meal replacement shake
Description: One bottle of Boost Original meal replacement shake.
Study: NCT05916053

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: 50.000 IU of vitamin D supplementation was prescribed for deficient/insufficient participants for a 3 month period.
Study: NCT06043492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: 10 x 2 min running at vVO2max, interspersed by 2 min recovery at 40% VO2max

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coninuous Running
Description: 40 min continuous running at lactate threshold

Intervention type: OTHER
Group type: OTHER
Intervention: Control Trial
Description: The participants will perform only the baseline and post acute-training evaluations, without performing exercise
Study: NCT05030571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DPMAS
Description: DPMAS circuit consist of Plasmaflo OP cartridge (Asahi Medical, Tokyo, Japan), Ion exchange resin hemoperfusion cartridge (BS330; Jafron, Zhuhai City, China), and Neutral adsorption resin hemoperfusion cartridge (HA330-II; Jafron, Zhuhai City, China)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment according to EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure 2017.
Study: NCT05912075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: prior to tolinapant (ASTX660) for 6 cycles over 12 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy LCRT
Description: 50-Gy total dose in 25 daily fractions of 2 Gy (5 days per week from Monday to Friday) for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOLINAPANT (ASTX660)
Description: starting from 14 days before the first dose of radiotherapy, for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOLINAPANT (ASTX660)
Description: starting from 14 days before the first dose of radiotherapy, for 10 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy SCRT
Description: total dose of 25 Gy, in 5 daily fractions of 5 Gy for 1 week (5 days from Monday-Friday)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPOX
Description: every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
Study: NCT06144541

Intervention type: OTHER
Intervention: Survey administration for Fitzpatrick skin type
Description: Survey administration for Fitzpatrick skin type

Intervention type: DEVICE
Intervention: Measurement of ITA based on SkinColorCatch instrument
Description: Measurement of ITA based on SkinColorCatch instrument
Study: NCT05437614

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micropulse diode laser cyclophotocoagulation in treatment of refractory Glaucoma
Description: Treatment of refractory Glaucoma by Micropulse diode laser cyclophotocoagulation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyclocryoablation in treatment of refractory Glaucoma
Description: Treatment of refractory Glaucoma by cyclocryoablation
Study: NCT05446051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV)
Description: Phase I Interventions：eRAPID-MV(TRAEs survey)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the telephone triage decision support system (TTDSS)
Description: Phase I Interventions：TTDSS
Study: NCT05421780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: autoclaved BSG-containing biscuits
Description: Consumption of autoclaved BSG-containing biscuits as breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bio-transformed BSG-containing biscuits
Description: Consumption of bio-transformed BSG-containing biscuits as breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control biscuits
Description: Consumption of plain biscuits as breakfast.
Study: NCT06480136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921 injection and adebrelimab injection
Description: The Treatment group receive SHR-A1921 injection combined with adebrelimab injection
Study: NCT06253247

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NanoChitosan impregnated Calcium Hydroxide
Description: NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NanoChitosan impregnated Calcium Hydroxide
Description: NanoChitosan impregnated Calcium Hydroxide used as an intracanal medication fro 7 days